secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-035886
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Q2 net loss $55.3M; FDA clears PM359 for CGD Phase 1/2 trial
---------------------------------------------------------------------------

- FDA cleared IND for PM359 (Prime Editor for chronic granulomatous disease); Phase 1/2 trial initiating, initial data expected 2025.
- Net loss $55.3M vs $42.4M YoY; R&D expenses $43.1M up from $34.6M; G&A $12.6M vs $10.7M.
- Cash, equivalents, investments & restricted cash $176.4M as of June 30, 2024 (up from $135.2M Dec 31, 2023).
- Promoted Mohammed Asmal, M.D., Ph.D. to Chief Medical Officer, effective immediately; he was SVP Head of Clinical since 2022.
- Pipeline milestones: liver IND/CTA expected H2 2025–H1 2026; ocular candidate nomination for RHO-RP in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024035886/0001628280-24-035886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024035886/prme-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer